- Home
- ACRS vs CRBU Comparison
ACRS vs CRBU Comparison
Compare ACRS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CRBU
- Stock Information
- Founded
- ACRS 2012
- CRBU 2011
- Country
- ACRS United States
- CRBU United States
- Employees
- ACRS N/A
- CRBU N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- ACRS Health Care
- CRBU Health Care
- Exchange
- ACRS Nasdaq
- CRBU Nasdaq
- Market Cap
- ACRS 198.2M
- CRBU 179.7M
- IPO Year
- ACRS 2015
- CRBU 2021
- Fundamental
- Price
- ACRS $1.89
- CRBU $2.68
- Analyst Decision
- ACRS Strong Buy
- CRBU Strong Buy
- Analyst Count
- ACRS 9
- CRBU 3
- Target Price
- ACRS $9.25
- CRBU $6.67
- AVG Volume (30 Days)
- ACRS 1.1M
- CRBU 1.3M
- Earning Date
- ACRS 11-05-2025
- CRBU 11-05-2025
- Dividend Yield
- ACRS N/A
- CRBU N/A
- EPS Growth
- ACRS N/A
- CRBU N/A
- EPS
- ACRS N/A
- CRBU N/A
- Revenue
- ACRS $16,789,000.00
- CRBU $9,121,000.00
- Revenue This Year
- ACRS N/A
- CRBU $8.06
- Revenue Next Year
- ACRS $7.02
- CRBU N/A
- P/E Ratio
- ACRS N/A
- CRBU N/A
- Revenue Growth
- ACRS N/A
- CRBU N/A
- 52 Week Low
- ACRS $1.05
- CRBU $0.66
- 52 Week High
- ACRS $5.17
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- ACRS 48.51
- CRBU 64.30
- Support Level
- ACRS $1.81
- CRBU $2.24
- Resistance Level
- ACRS $1.94
- CRBU $2.39
- Average True Range (ATR)
- ACRS 0.09
- CRBU 0.19
- MACD
- ACRS -0.01
- CRBU 0.04
- Stochastic Oscillator
- ACRS 27.51
- CRBU 94.75
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.